Literature DB >> 24792742

Meta-analysis of time-related benefits of statin therapy in patients with acute coronary syndrome undergoing percutaneous coronary intervention.

Eliano Pio Navarese1, Mariusz Kowalewski2, Felicita Andreotti3, Marleen van Wely4, Cyril Camaro4, Michalina Kolodziejczak5, Bartosz Gorny2, Jeffrey Wirianta6, Jacek Kubica5, Malte Kelm7, Menko-Jan de Boer4, Harry Suryapranata4.   

Abstract

Patients with acute coronary syndromes (ACSs) still experience high rates of recurrent coronary events, particularly, early in their presentation. Statins yield substantial cardiovascular benefits, but the optimal timing of their administration, before or after percutaneous coronary intervention (PCI), remains unclear. We aimed to perform a meta-analysis of randomized controlled trials of statin administration before or after PCI versus no statin or low-dose statin in patients with ACS. Primary end points were 30-day all-cause mortality and 30-day myocardial infarction (MI) stratified by pre- and post-PCI statin administration. Secondary end points were major adverse cardiac events (MACEs) or major adverse cardiac and cerebrovascular events (MACCEs). Long-term analysis beyond 30 days was also performed. Twenty randomized controlled trials enrolling 8,750 patients were included. At 30 days, the rate of MI was significantly lower in the statin group (odds ratio [OR] 0.67, 95% confidence interval [CI] 0.53 to 0.84, p = 0.0007) with a trend toward reduced mortality (p = 0.06) and significant reductions in MACE and MACCE compared with no or low-dose statin. The 30-day incidence of MI was markedly lower when statins were administered before PCI (OR 0.38, 95% CI 0.24 to 0.59, p <0.0001) rather than after PCI (p = 0.28). The direction and magnitude of the estimates for before and after PCI versus no statin or low-dose statin were sustained at long term, not reaching statistical significance for MI (OR 0.81, 95% CI 0.65 to 1.01, p = 0.06) but with significant reductions in MACE (p = 0.0002). By meta-regression, earlier statin administration correlated significantly with lower risk of MI, MACE, and MACCE at 30 days. In conclusion, the present meta-analysis indicates a time-related impact of statin therapy on clinical outcomes of patients with ACS undergoing PCI: the earlier the administration before PCI, the greater the benefits.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24792742     DOI: 10.1016/j.amjcard.2014.02.034

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  15 in total

1.  Statin-associated ocular disorders: the FDA and ADRAC data.

Authors:  Vinci Mizranita; Eko Harry Pratisto
Journal:  Int J Clin Pharm       Date:  2015-05-05

2.  PURLs: prescribing statins for patients with ACS? No need to wait.

Authors:  Hanna Gov-Ari; James J Stevermer
Journal:  J Fam Pract       Date:  2014-12       Impact factor: 0.493

3.  Early treatment with high-potency statins in patients with acute coronary syndrome-an example of personalized medicine.

Authors:  Emanuel Harari; Alon Eisen
Journal:  J Thorac Dis       Date:  2018-06       Impact factor: 2.895

4.  Timing of high intensity statin for acute coronary syndrome: how earlier initiation makes better?

Authors:  Choongki Kim; Donghoon Choi
Journal:  J Thorac Dis       Date:  2018-07       Impact factor: 2.895

5.  Timing of Loading Dose of Atorvastatin in Patients Undergoing Percutaneous Coronary Intervention for Acute Coronary Syndromes: Insights From the SECURE-PCI Randomized Clinical Trial.

Authors:  Renato D Lopes; Pedro G M de Barros E Silva; Isabella de Andrade Jesuíno; Eliana Vieira Santucci; Lilian Mazza Barbosa; Lucas Petri Damiani; Renato Hideo Nakagawa Santos; Ligia Nasi Laranjeira; Frederico Toledo Campo Dall Orto; Pedro Beraldo de Andrade; Igor Ribeiro de Castro Bienert; John H Alexander; Christopher B Granger; Otavio Berwanger
Journal:  JAMA Cardiol       Date:  2018-11-01       Impact factor: 14.676

6.  Long-term statin use before primary percutaneous coronary intervention improves treatment outcomes of acute myocardial infarction.

Authors:  Ruiwei Guo; Lixia Yang; Lihua Mu; Xianfeng Pan; Feng Qi
Journal:  Exp Ther Med       Date:  2017-02-22       Impact factor: 2.447

7.  Clinical impact of statin intensity according to age in patients with acute myocardial infarction.

Authors:  Kyusup Lee; Myunhee Lee; Dae-Won Kim; Jinseob Kim; Sungmin Lim; Eun Ho Choo; Chan Joon Kim; Chul Soo Park; Hee Yeol Kim; Ki-Dong Yoo; Doo Soo Jeon; Kiyuk Chang; Ho Joong Youn; Wook-Sung Chung; Min Chul Kim; Myung Ho Jeong; Youngkeun Ahn; Jongbum Kwon; Mahn-Won Park
Journal:  PLoS One       Date:  2022-06-15       Impact factor: 3.752

Review 8.  Lipid Lowering Therapy for Acute Coronary Syndrome and Coronary Artery Disease: Highlights of the 2017 Taiwan Lipid Guidelines for High Risk Patients.

Authors:  Yi-Heng Li; Ting-Hsing Chao; Ping-Yen Liu; Kwo-Chang Ueng; Hung-I Yeh
Journal:  Acta Cardiol Sin       Date:  2018-09       Impact factor: 2.672

9.  Effect of moderate-intensity statin therapy on plaque inflammation in patients with acute coronary syndrome: A prospective interventional study evaluated by 18F-FDG PET/CT of the carotid artery.

Authors:  Chan Joon Kim; Eun Ji Han; Eun-Ho Chu; Byung-Hee Hwang; Jin-Jin Kim; Ki-Bae Seung; Sung Hoon Kim; Joon Hyun O; Kiyuk Chang
Journal:  Cardiol J       Date:  2018-07-16       Impact factor: 2.737

Review 10.  Pitavastatin: Coronary Atherosclerotic Plaques Changes and Cardiovascular Prevention.

Authors:  Francesco Fici; Gokhan Faikoglu; Bahar Arican Tarim; Nicolas Roberto Robles; Kostas Tsioufis; Guido Grassi; Barış Gungor
Journal:  High Blood Press Cardiovasc Prev       Date:  2022-01-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.